Breast cancer is one of the most commonly diagnosed cancers in women, and the disease affects many women's lives every day. Since the final stage of the disease is very difficult to cure, we need to consider different approaches to overcome this disease, such as prevention at an early stage. Preventive approaches, as shown by the successful clinical trials of selective estrogen receptor modulators (SERMs) for the prevention of estrogen receptor (ER) positive breast cancer, have contributed to improvement in the management of this disease. However, the benefit of these SERMs in the treatment of breast cancer is still far from a total cure, in particular with ER negative breast cancer. We have been interested in developing new agents based on their mechanisms of action, and we propose studying a nuclear receptor and its ligands for chemoprevention of breast cancer. The vitamin D receptor (VDR) is a member of the nuclear receptor family, and its ligands have been implicated in the regulation of many biological processes including cell growth, differentiation, and apoptosis in the breast, colon, prostate, and other organs. Although the ability of vitamin D analogs to arrest growth in many cancer cell types has been reported, the effects and the mechanisms of action of vitamin D derivatives in ER negative breast cancer remains to be investigated. Unique features of this proposal are studies with novel vitamin D analogs with decreased toxicity that have effects independent of estrogen receptor, and the utilization of the human MCF10 progressive breast cancer model that resembles and covers the different spectrum of breast carcinogenesis. We will determine the ability of novel vitamin D analogs to prevent breast cancer in an in vivo xenograft model using nude mice, and further investigate the role of the vitamin D analogs on the regulation of transforming growth factor-( (TGF-()/Smad signaling in these cells. The goal of this proposal is to develop novel ligands for the vitamin D receptor as potential chemopreventive agents that can ultimately be used to prevent breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Research Grants (R03)
Project #
5R03CA112642-02
Application #
6951896
Study Section
Special Emphasis Panel (ZCA1-SRRB-Q (O1))
Program Officer
Steele, Vernon E
Project Start
2004-09-22
Project End
2006-08-31
Budget Start
2005-09-01
Budget End
2006-08-31
Support Year
2
Fiscal Year
2005
Total Cost
$77,750
Indirect Cost
Name
Rutgers University
Department
Biology
Type
Schools of Pharmacy
DUNS #
001912864
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Lee, Hong Jin; So, Jae-Young; DeCastro, Andrew et al. (2010) Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling. J Steroid Biochem Mol Biol 121:408-12
Paul, Shiby; Rimando, Agnes M; Lee, Hong Jin et al. (2009) Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells. Cancer Prev Res (Phila) 2:650-7
Lee, Hong Jin; Ju, Jihyeung; Paul, Shiby et al. (2009) Mixed tocopherols prevent mammary tumorigenesis by inhibiting estrogen action and activating PPAR-gamma. Clin Cancer Res 15:4242-9
Lee, Hong Jin; Paul, Shiby; Atalla, Nadi et al. (2008) Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity. Cancer Prev Res (Phila) 1:476-84
Lee, Hong Jin; Ji, Yan; Paul, Shiby et al. (2007) Activation of bone morphogenetic protein signaling by a Gemini vitamin D3 analogue is mediated by Ras/protein kinase C alpha. Cancer Res 67:11840-7
Suh, Nanjoo; Paul, Shiby; Hao, Xingpei et al. (2007) Pterostilbene, an active constituent of blueberries, suppresses aberrant crypt foci formation in the azoxymethane-induced colon carcinogenesis model in rats. Clin Cancer Res 13:350-5
Lee, Hong Jin; Wislocki, Andrew; Goodman, Catherine et al. (2006) A novel vitamin D derivative activates bone morphogenetic protein signaling in MCF10 breast epithelial cells. Mol Pharmacol 69:1840-8
Ji, Yan; Lee, Hong Jin; Goodman, Catherine et al. (2006) The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells. Mol Cancer Ther 5:1452-8
Banach-Petrosky, Whitney; Ouyang, Xuesong; Gao, Hui et al. (2006) Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clin Cancer Res 12:5895-901
Lee, Hong Jin; Liu, Hao; Goodman, Catherine et al. (2006) Gene expression profiling changes induced by a novel Gemini Vitamin D derivative during the progression of breast cancer. Biochem Pharmacol 72:332-43